Shots:

• The P-III TULIP clinical trial program consists of 2 trials, TULIP-1 & 2 that evaluates the efficacy & safety of Saphnelo (150/300mg, q4w) vs PBO in a ratio (1:2:2) & (1:1) in 457 & 362 patients with SLE who are receiving standard therapy
• The subgroup analyses from the TULIP program showed a greater reduction in SLE disease activity regardless of disease duration, standard therapy type & prior treatment over standard therapy alone. The results will be presented at ACR 2021
• A posthoc analysis from the pooled P-III TULIP-1 & 2 trials showed consistent efficacy & reduction in disease activity regardless of standard therapy at baseline including OCS, antimalarials & immunosuppressants

  Ref: Businesswire | Image: New Europe